US Stock Insider Trading | Caribou Biosciences disclosed four insider trading transactions on February 24

K-LinePoet · 2026-03-08T08:07:12+00:00

Caribou Biosciences disclosed multiple insider trading activities on February 24, 2026, including Khan Ruhi Ahmad and others selling shares on that day, indicating active trading behavior among company executives. The company focuses on biopharmaceuticals based on genome editing cell therapies.

K-LinePoet

2026-03-08 08:07:12

Abstract generation in progress

On February 24, 2026, Caribou Biosciences (CRBU) disclosed four insider trading transactions. Executive Khan Ruhi Ahmad sold 6,938 shares on that date.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Executive	Khan Ruhi Ahmad	February 24, 2026	Sell	6,938	1.96	$13,600
February 24, 2026	Executive	MCCLUNG BARBARA G	February 24, 2026	Sell	6,938	1.96	$13,600
February 24, 2026	Executive	Kelly Timothy P	February 24, 2026	Sell	3,147	1.96	$6,168.12
February 24, 2026	Executive	Albertson Tina M.	February 24, 2026	Sell	1,066	1.96	$2,089.36
March 17, 2025	Director	Haurwitz Rachel E.	March 14, 2025	Buy	20,000	1.02	$20,400
February 21, 2025	Executive	MCCLUNG BARBARA G	February 21, 2025	Sell	3,564	1.35	$4,811.40
February 21, 2025	Executive	Khan Ruhi Ahmad	February 21, 2025	Sell	3,564	1.35	$4,811.40
February 21, 2025	Executive	Kanner Steven	February 21, 2025	Sell	3,564	1.35	$4,811.40
January 30, 2025	Executive	Ryali Sriram	January 29, 2025	Buy	17,400	1.42	$24,700
February 6, 2024	Executive	Kanner Steven	February 6, 2024	Buy	30,600	2.69	$82,300

[Company Profile]

Caribou Biosciences, Inc. was incorporated in Delaware in October 2011. The company is a clinical-stage biopharmaceutical firm dedicated to developing next-generation genome editing cell therapies using its novel CRISPR platform, CRISPR hybrid RNA-DNA or chRDNA, to change the lives of patients suffering from devastating diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes